These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 2555536)
21. Antigenic cross-reactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus. Balachandran N; Oba DE; Hutt-Fletcher LM J Virol; 1987 Apr; 61(4):1125-35. PubMed ID: 3029407 [TBL] [Abstract][Full Text] [Related]
22. [Prokaryotic expression and characterization of N-terminal truncated glycoprotein gp85 of Epstein-Barr virus]. Tu XD; Wu YS; Qiu LX; Lian YZ; Cheng F; Lan FH; Zhu ZY Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Feb; 23(2):110-2. PubMed ID: 17286900 [TBL] [Abstract][Full Text] [Related]
23. Effect of monoclonal antibodies to Epstein-Barr virus envelope glycoproteins on Epstein-Barr virus neutralization and binding to target cell receptors. A comparative analysis. Stocco R; Sauvageau G; Stefanescu I; Menezes J Intervirology; 1990; 31(5):295-300. PubMed ID: 1703135 [TBL] [Abstract][Full Text] [Related]
24. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. Nemerow GR; McNaughton ME; Cooper NR J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485 [TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus-lymphoid cell interactions. III. Effect of concanavalin A and saccharides on Epstein-Barr virus penetration. Khélifa R; Menezes J J Virol; 1982 May; 42(2):402-10. PubMed ID: 6283164 [TBL] [Abstract][Full Text] [Related]
26. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule. Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592 [TBL] [Abstract][Full Text] [Related]
27. Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen. Kishishita M; Luka J; Vroman B; Poduslo JF; Pearson GR Virology; 1984 Mar; 133(2):363-75. PubMed ID: 6324457 [TBL] [Abstract][Full Text] [Related]
28. Two large virion envelope glycoproteins mediate Epstein-Barr virus binding to receptor-positive cells. Wells A; Koide N; Klein G J Virol; 1982 Jan; 41(1):286-97. PubMed ID: 6283120 [TBL] [Abstract][Full Text] [Related]
29. Model for studying virus attachment: identification and quantitation of Epstein-Barr virus-binding cells by using biotinylated virus in flow cytometry. Inghirami G; Nakamura M; Balow JE; Notkins AL; Casali P J Virol; 1988 Jul; 62(7):2453-63. PubMed ID: 2836625 [TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity. Khyatti M; Patel PC; Stefanescu I; Menezes J J Virol; 1991 Feb; 65(2):996-1001. PubMed ID: 1846213 [TBL] [Abstract][Full Text] [Related]
31. Superinfection of epithelial hybrid cells (D98/HR-1, NPC-KT, and A2L/AH) with Epstein-Barr virus and the relationship to the C3d receptor. Takimoto T; Sato H; Ogura H; Miyawaki T; Glaser R Cancer Res; 1986 May; 46(5):2541-4. PubMed ID: 3008992 [TBL] [Abstract][Full Text] [Related]
32. Identification of the Epstein-Barr virus gp85 gene. Heineman T; Gong M; Sample J; Kieff E J Virol; 1988 Apr; 62(4):1101-7. PubMed ID: 2831372 [TBL] [Abstract][Full Text] [Related]
33. Charge and pH effect on the early events of Epstein-Barr virus fusion with lymphoblastoid cells (Raji). Pozzi D; Faggioni A; Zompetta C; De Ros I; Lio S; Lisi A; Ravagnan G; Frati L; Grimaldi S Intervirology; 1992; 33(4):173-9. PubMed ID: 1326496 [TBL] [Abstract][Full Text] [Related]
34. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model. Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y Front Immunol; 2018; 9():932. PubMed ID: 29765376 [TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21. Yoshiyama H; Imai S; Shimizu N; Takada K J Virol; 1997 Jul; 71(7):5688-91. PubMed ID: 9188650 [TBL] [Abstract][Full Text] [Related]
36. Expression of the Epstein-Barr virus (EBV) receptor on the surface of cells infected with EBV derived from nasopharyngeal carcinoma. Takimoto T; Umeda R Acta Virol; 1989 Aug; 33(4):314-9. PubMed ID: 2574937 [TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus (EBV) receptor implantation onto human B lymphocytes changes immunoglobulin secretion patterns induced by EBV infection. Tsukuda K; Volsky DJ; Shapiro IM; Klein G Eur J Immunol; 1982 Jan; 12(1):87-90. PubMed ID: 6277643 [TBL] [Abstract][Full Text] [Related]
38. Early events of fusion between Epstein Barr virus and human lymphoblastoid cells (Raji) detected by R18 fluorescence dequenching measurements. Pozzi D; Zompetta C; Faggioni A; Lisi A; De Ros I; Ravagnan G; Grimaldi S Membr Biochem; 1990; 9(4):239-51. PubMed ID: 1967072 [TBL] [Abstract][Full Text] [Related]
39. Membrane anchoring of Epstein-Barr virus gp42 inhibits fusion with B cells even with increased flexibility allowed by engineered spacers. Rowe CL; Chen J; Jardetzky TS; Longnecker R mBio; 2015 Jan; 6(1):. PubMed ID: 25564465 [TBL] [Abstract][Full Text] [Related]
40. Biochemical and antigenic analysis of the Epstein Barr virus/C3d receptor (CR2). Siaw MF; Nemerow GR; Cooper NR J Immunol; 1986 Jun; 136(11):4146-51. PubMed ID: 3009616 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]